Back
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.
Journal article

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.

  • Krähenbühl L Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Goldinger SM Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Mangana J Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Kerl K Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Chevolet I Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Brochez L Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Horak C Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Levesque M Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland.
  • Dummer R Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch.
  • Cheng PF Department of Dermatology University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland. Electronic address: phil.cheng@usz.ch.
Show more…
  • 2018-01-15
Published in:
  • Neoplasia (New York, N.Y.). - 2018
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
B7-H1 Antigen
Biomarkers, Tumor
Female
Follow-Up Studies
Humans
Immunotherapy
Indoleamine-Pyrrole 2,3,-Dioxygenase
Longitudinal Studies
Male
Melanoma
Middle Aged
Molecular Targeted Therapy
Prognosis
Survival Rate
Young Adult
English A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1 expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies and might be used to support treatment decisions.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/91151
Statistics
Document views: 18 File downloads: